. This has led to the conclusion that S100A1 is a physiologically important activator/sensitizer of RyR1 release in skeletal muscle.
Yamaguchi et al. (12) bound Ca 2ϩ ; Apo-CaM) exerts an activating effect on RyR1 that is weaker than that of S100A1 (Fig. 1C) and when both are present, the S100A1 effect dominates (Fig. 1D) . When [Ca 2ϩ ] i is elevated as with repeated action potentials or depolarizations, S100A1 might limit the inhibitory effect of Ca 2ϩ -CaM on RyR1 (Fig. 1E) . If the [Ca 2ϩ ] i elevation is prolonged, Ca 2ϩ -CaM may overcome or displace S100A1 and produce a more tonic inhibition of the RyR1 (Fig. 1F) . Indeed, this may be the situation in the S100A1 Ϫ/Ϫ mice, where tetanic force and [Ca 2ϩ ] i are suppressed (4, 5) . In the Ryr D/D mouse where both the activating effects of S100A1 (and CaM) and the inhibitory effects of Ca 2ϩ -CaM are abolished (Fig. 1G) , the twitch Ca 2ϩ transient and force are depressed (loss of S100A1 activation) and tetanic summation is enhanced (loss of Ca 2ϩ -CaM-dependent inactivation). Detailed testing and molecular analysis of some aspects of this framework are still needed, but this provides a simple working hypothesis for such testing.
Inactivation of RyR1 during sustained depolarization is slowed in the Ryr D/D mice, but the difference from WT is rather modest (see their Fig. 10B ). While this is consistent with CaM contributing to RyR1 inactivation, it indicates that it may not be the dominant pathway for RyR1 inactivation. On the other hand, it is possible that this Ca 2ϩ -CaM dependent inactivation is a more absorbing kind of inactivation that is longlasting between activations. That may explain the more pronounced increase in [Ca 2ϩ ] i and force during tetanic stimulation (treppe) in the Ryr D/D versus WT mice. That is, Ca 2ϩ -CaM may limit the normal tetanic SR Ca 2ϩ release in WT, and that effect is relieved in the Ryr D/D mouse. Notably, the S100A1-knockout mouse (S100A1 Ϫ/Ϫ ) has an even more profound limitation in the tetanic treppe than WT mice (5). This may mean that S100A1 in WT mice limits the ability of Ca 2ϩ -CaM to inactivate RyR1. That would be consistent with a role of S100A1 to both activate RyR1 and prevent the Ca 2ϩ -CaM inhibitory effect (Fig. 1, B, D , and E), and both effects could be related to the competition between S100A1 and CaM for binding to the RyR1 (10). This suggests an additional experimental test. If in the WT mouse substantial RyR1 inhibition develops during tetany via Ca 2ϩ -CaM displacement of S100A1 (Fig. 1F) , then a posttetanic twitch may be more depressed than one after a longer pause where S100A1 might reinsinuate itself (Fig. 1D ). This effect would not be expected in the Ryr D/D mice and might be reduced in S100A1 Ϫ/Ϫ mice. The cardiac muscle RyR2 also binds both CaM and S100A1, but the effects are a bit different. Both CaM and S100A1 appear to exhibit mainly inhibitory effects on RyR2 at diastolic [Ca 2ϩ ] i and are thought to limit diastolic SR Ca 2ϩ release which can otherwise be arrhythmogenic and also can reduce SR Ca 2ϩ content available for release (e.g., Refs. 3 and 7). Both CaM and S100A1 inhibit resting Ca 2ϩ sparks (diastolic leak) in cardiac myocytes, but S100A1 also enhances the fractional SR Ca 2ϩ release during ECC. So there may be some degree of similarity regarding the CaM/S100A1 effects on RyR2 versus RyR1. S100A1 also interacts with the SERCA2a-phospholamban complex (possibly relieving phospholamban inhibition), the myofilament protein titin (it may reduce myofilament stiffness), and mitochondria (it may also enhance energy production). Moreover, S100A1 expression declines in heart failure and adenoviral expression of S100A1 in failing cardiac myocytes can exhibit beneficial effects (7) .
This study has helped to clarify the interaction of CaM and S100A1 signaling at the RyR1, but there is key fundamental information still missing in terms of understanding the dynamics of this interplay in intact skeletal (and cardiac) muscle. The absolute concentrations of both CaM and S100A1 at transverse tubule-SR junctions in skeletal muscle are not known, nor are the fractional occupancies of RyR1 sites by these two modulatory ligands under physiological conditions. There may also be conditions where this occupancy and competition changes (e.g., during exercise, oxidative stress, fatigue, disease). Regardless, the study here shows how the interplay of CaM and S100A1 effects can fine tune skeletal muscle ECC.
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